Louisiana House Bill HR292

Louisiana 2025 Regular Session

• Introduced: 6/4/25
• Passed: 6/10/25

Caption

Urges and requests the La. Dept. of Health to increase Medicaid coverage for healthcare services required by individuals with gestational diabetes mellitus

Summary

House Resolution 292 urges and requests the Louisiana Department of Health (LDH) to study whether its Medicaid coverage policy and fee schedule should be updated to better cover continuous glucose monitoring (CGM) services for pregnant Medicaid recipients who are at risk for, or otherwise qualify with, gestational diabetes mellitus (GDM). The resolution is focused on maternal health and asks LDH to examine coverage policy options, the cost of expanding coverage, the potential long-term savings to the healthcare system, and the health risks of leaving current policy unchanged. It also directs LDH to report its findings to the House Committee on Health and Welfare by January 1, 2026, unless the department chooses to update the policy sooner. The resolution does not itself change Medicaid eligibility or benefits, but it signals legislative interest in expanding access to CGM for maternal patients with GDM. It references rising GDM rates in the Louisiana Medicaid population, the health benefits of CGM in managing blood sugar, and the possibility that existing incentive-based reimbursement arrangements with managed care organizations and hospitals could help support broader coverage. The measure is advisory in nature, but it could lead to future administrative or legislative changes affecting Medicaid coverage rules, reimbursement practices, and maternal health services in Louisiana.

Impact

HR 292 has no immediate statutory effect because it is a resolution rather than a law, but it directs LDH to evaluate potential changes to Medicaid coverage policy and fee schedules for CGM services related to gestational diabetes. If LDH acts on the study or updates policy, the practical impact could be expanded Medicaid access for pregnant patients at risk for or diagnosed with GDM, with possible effects on provider reimbursement, managed care arrangements, and maternal health outcomes. The resolution also frames the issue in terms of potential cost savings and prevention of pregnancy complications, which may influence future budget or policy decisions.

Sentiment

The overall sentiment around the resolution appears strongly supportive. The House passed HR 292 unanimously, 92-0, indicating broad agreement that LDH should study whether Medicaid coverage for CGM should be expanded for maternal patients with gestational diabetes. The bill text itself emphasizes public health benefits, rising prevalence of GDM, and possible long-term savings, all of which suggest a favorable policy environment for the proposal.

Contention

There is little visible contention in the available record, and no committee transcript is provided. The main policy question embedded in the resolution is whether expanding Medicaid CGM coverage should be limited to insulin-dependent GDM patients or extended to all at-risk or otherwise qualifying maternal patients. A related point of discussion is cost: the resolution estimates expansion could cost between $500,000 and $1 million, while also suggesting existing reimbursement mechanisms might offset some of that expense. Any disagreement would likely center on fiscal impact, coverage scope, and whether the evidence supports broader Medicaid reimbursement for CGM.